Use of aliskiren in a ‘real-life’ model of hypertension management
Article 2011 en
Authors
MV
Massimo Volpe
GT
Giuliano Tocci
FB
Francesca Bianchini
Abstract
1 min read
Although data derived from national registries need to be interpreted with caution, the Italian Web-based drug-monitoring system provided information on 'real-life' use of aliskiren in hypertension. In this uncontrolled, high-risk treated hypertensive population, SBP and DBP levels recorded during treatment with aliskiren were consistently lower than those recorded at entry visits in a context of a very low rate of reported side-effects.
Wiktoria Wojciechowska, Marek Rajzer, Thomas Weber, Marzena Chrostowska, Michael Doumas, Jean-Baptiste de Fréminville, Jacek Lewandowski, Grégoire Wuerzner, Maria Gosk -Przybylek, Gianfranco Parati, Patricia Van der Niepen, Thomas Kahan, Michael Bursztyn, Alexandre Persu, George S. Stergiou, Grzegorz Bilo, Guıdo Grassı, Giuseppe Mancia, Reinhold Kreutz, Andrzej Januszewicz
Bryan Williams, Giuseppe Mancia, Wilko Spiering, Enrico G. Caiani, Michel Azizi, Michel Burnier, D Clément, António Coca, Giovanni de Simone, Anna F. Dominiczak, Thomas Kahan, Felix Mahfoud, Josep Redón, Luís M. Ruilope, Alberto Zanchetti, Mary Kerins, Sverre E. Kjeldsen, Reinhold Kreutz, Stéphane Laurent, Professor Gregory Lip, Richard McManus, Krzysztof Narkiewicz,
Discussion(0)
No comments yet. Be the first to comment.